Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 30 ... of the ABSORB clinical trial, demonstrating that its fully bioabsorbable drug eluting coronary stent successfully treated coronary artery disease and was absorbed into the walls of treated ...
2009 NOV 30 ... either a placebo or the investigational drug cangrelor during procedures to reopen coronary artery blockages. Cangrelor is a potent, fast-acting and reversible anti-clotting drug ... all-cause mortality and need for revascularization, but it reduced mortality and in-stent blood clots, researchers reported in a late-breaking clinical trial presentation at the ...
2009 NOV 30 ... risk of some clinically meaningful ischemic events in patients undergoing percutaneous coronary intervention (PCI)," said Robert A. Harrington, M.D., principal investigator of the ... Institute in Durham NC. "That includes a possible reduction in Q wave infarction and stent thrombosis." In CHAMPION PCI -- a phase III, multi-national (200 sites, 18 ...
2009 NOV 30 ... midst of ST-elevation heart attacks (STEMI) and were scheduled for primary percutaneous coronary intervention (PCI) with stenting received the investigational drug ticagrelor or ... of risk of 18 percent. Likewise, the risk of new myocardial infarction and the risk of stent thrombosis were also reduced. "Furthermore, the benefit is not solely achieved during ...
2009 NOV 30 ... Results from a new study showed patients with type 2 diabetes mellitus who also had coronary artery disease (CAD) and received a 60 mg loading dose and 10 mg maintenance dose of ... for clopidogrel therapy (more than 12 months after an acute coronary event or bare metal stent placement and no drug eluting stent in place). The relationship between inhibition of ...
2009 NOV 30 ... Results of a Mayo Clinic study show the incidence of stroke or mini-stroke related to a coronary angioplasty (http://www.mayoclinic.org/heart-catheterization/types.html) remained steady ... and inflated to unclog and widen the artery. In some cases, a small metal coil called a stent is placed in the artery to keep it propped open. In a retrospective study ...
2009 NOV 30 ... present study, we evaluated the application of a short drug-eluting balloon-expandable coronary stent for the endovascular treatment of these frequent lesions. In a period of 23 months, 48 ...
2009 NOV 30 ... Vascular, USA). A total of 247 consecutive patients with 293 de novo lesions in native coronary arteries were treated with cobalt chromium Vision (n=184; stent diameter 2.75 mm to 4.0 ...
2009 NOV 30 ... laser has been successfully applied to complex atherosclerotic plaques in acute coronary syndromes; however, its role in debulking in left main coronary artery disease has not ... six (30%) ostial stenoses, and one (5%) mid-portion lesions. Two (10%) patients had in-stent re-stenosis of the entire length of the LMCA. Small (0.7 mm-1.4 mm) excimer laser ...
2009 NOV 30 ... option in two clinical guideline updates: one for patients receiving percutaneous coronary intervention (PCI) and a second one for patients with ST elevation myocardial infarction ... the chance of having another thrombotic cardiovascular event such as heart attack or stent-related blood clot for patients with acute coronary syndromes (ACS) who are managed with ...
2009 NOV 30 ... option in two clinical guideline updates: one for patients receiving percutaneous coronary intervention (PCI) and a second one for patients with ST elevation myocardial infarction ... the chance of having another thrombotic cardiovascular event such as heart attack or stent-related blood clot for patients with acute coronary syndromes (ACS) who are managed with ...
2009 NOV 30 ... or bradycardia (heart rate <60 beats/min). CBA angioplasty was carried out using CB coronary device, 0.014 inch compatible, from 3 to 4 mm or CB peripheral device, 0.018 inch ... concluded: "Postprocedural Doppler ultrasound scan showed one case (2%) of in-stent restenosis in group 1 representing early failure due to recoil, and only I (1.92%) ...
2009 NOV 30 ... significant coronary artery stenosis on angiography. He was treated with drug-eluting coronary stent placement," researchers in Seoul, South Korea report. "Clopidogrel was ...
2009 NOV 23 ... conference. The vProtect™ Luminal Shield is a novel self-expanding coronary stent system that received CE Mark certification in August, 2009 for use in improving coronary ...
2009 NOV 23 ... to recent research published in the American Heart Journal, "In the treatment of coronary artery disease, a ''pro-healing'' approach for prevention of in-stent restenosis and ...
2009 NOV 23 ... therapy with low-molecular-weight heparin was applied in all cases. The patient with the coronary stent who was managed with reduced-dose dalteparin developed postoperative intracranial ...
